CONTEXT: Antidepressant medications represent the best established treatment for major depressive disorder, but there is little evidence that they have a specific pharmacological effect relative to pill placebo for patients with less severe depression. OBJECTIVE: To estimate the relative benefit of medication vs placebo across a wide range of initial symptom severity in patients diagnosed with depression. DATA SOURCES: PubMed, PsycINFO, and the Cochrane Library databases were searched from January 1980 through March 2009, along with references from meta-analyses and reviews. STUDY SELECTION: Randomized placebo-controlled trials of antidepressants approved by the Food and Drug Administration in the treatment of major or minor depressive disorder were selected. Studies were included if their authors provided the requisite original data, they comprised adult outpatients, they included a medication vs placebo comparison for at least 6 weeks, they did not exclude patients on the basis of a placebo washout period, and they used the Hamilton Depression Rating Scale (HDRS). Data from 6 studies (718 patients) were included. DATA EXTRACTION: Individual patient-level data were obtained from study authors. RESULTS: Medication vs placebo differences varied substantially as a function of baseline severity. Among patients with HDRS scores below 23, Cohen d effect sizes for the difference between medication and placebo were estimated to be less than 0.20 (a standard definition of a small effect). Estimates of the magnitude of the superiority of medication over placebo increased with increases in baseline depression severity and crossed the threshold defined by the National Institute for Clinical Excellence for a clinically significant difference at a baseline HDRS score of 25. CONCLUSIONS: The magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms. For patients with very severe depression, the benefit of medications over placebo is substantial.
CONTEXT: Antidepressant medications represent the best established treatment for major depressive disorder, but there is little evidence that they have a specific pharmacological effect relative to pill placebo for patients with less severe depression. OBJECTIVE: To estimate the relative benefit of medication vs placebo across a wide range of initial symptom severity in patients diagnosed with depression. DATA SOURCES: PubMed, PsycINFO, and the Cochrane Library databases were searched from January 1980 through March 2009, along with references from meta-analyses and reviews. STUDY SELECTION: Randomized placebo-controlled trials of antidepressants approved by the Food and Drug Administration in the treatment of major or minor depressive disorder were selected. Studies were included if their authors provided the requisite original data, they comprised adult outpatients, they included a medication vs placebo comparison for at least 6 weeks, they did not exclude patients on the basis of a placebo washout period, and they used the Hamilton Depression Rating Scale (HDRS). Data from 6 studies (718 patients) were included. DATA EXTRACTION: Individual patient-level data were obtained from study authors. RESULTS: Medication vs placebo differences varied substantially as a function of baseline severity. Among patients with HDRS scores below 23, Cohen d effect sizes for the difference between medication and placebo were estimated to be less than 0.20 (a standard definition of a small effect). Estimates of the magnitude of the superiority of medication over placebo increased with increases in baseline depression severity and crossed the threshold defined by the National Institute for Clinical Excellence for a clinically significant difference at a baseline HDRS score of 25. CONCLUSIONS: The magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms. For patients with very severe depression, the benefit of medications over placebo is substantial.
Authors: M C Wichers; D Q C M Barge-Schaapveld; N A Nicolson; F Peeters; M de Vries; R Mengelers; J van Os Journal: Neuropsychopharmacology Date: 2008-05-21 Impact factor: 7.853
Authors: Daniel Z Lieberman; Stuart A Montgomery; Karen A Tourian; Claudine Brisard; Gregory Rosas; Krishna Padmanabhan; Jean-Michel Germain; Bruno Pitrosky Journal: Int Clin Psychopharmacol Date: 2008-07 Impact factor: 1.659
Authors: Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal Journal: N Engl J Med Date: 2008-01-17 Impact factor: 91.245
Authors: Michelle J Pearce; Harold G Koenig; Clive J Robins; Bruce Nelson; Sally F Shaw; Harvey J Cohen; Michael B King Journal: Psychotherapy (Chic) Date: 2014-11-03
Authors: Barbara L Brody; Linda C Field; Anne-Catherine Roch-Levecq; Christine Y Moutier; Steven D Edland; Stuart I Brown Journal: Ann Clin Psychiatry Date: 2011-11 Impact factor: 1.567
Authors: Mark Hyman Rapaport; Andrew A Nierenberg; Robert Howland; Christina Dording; Pamela J Schettler; David Mischoulon Journal: J Psychiatr Res Date: 2011-05-31 Impact factor: 4.791
Authors: Lea T Drye; Barbara K Martin; Constantine E Frangakis; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos Journal: Int J Geriatr Psychiatry Date: 2011-06 Impact factor: 3.485
Authors: Jonathan Posner; David J Hellerstein; Inbal Gat; Anna Mechling; Kristin Klahr; Zhishun Wang; Patrick J McGrath; Jonathan W Stewart; Bradley S Peterson Journal: JAMA Psychiatry Date: 2013-04 Impact factor: 21.596
Authors: Marjan J M Hummel; Fabian Volz; Jeannette G van Manen; Marion Danner; Charalabos-Markos Dintsios; Maarten J Ijzerman; Andreas Gerber Journal: Patient Date: 2012 Impact factor: 3.883